Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Repotrectinib by Bristol-Myers Squibb for Non-Small Cell Lung Carcinoma: Likelihood of Approval
Repotrectinib is under clinical development by Bristol-Myers Squibb and currently in Phase III for Non-Small Cell Lung Carcinoma. According to...
Repotrectinib by Bristol-Myers Squibb for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval
Repotrectinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Anaplastic Large Cell Lymphoma (ALCL). According...
Repotrectinib by Bristol-Myers Squibb for Central Nervous System (CNS) Tumor: Likelihood of Approval
Repotrectinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Central Nervous System (CNS) Tumor. According...
Repotrectinib by Bristol-Myers Squibb for Thyroid Cancer: Likelihood of Approval
Repotrectinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Thyroid Cancer. According to GlobalData, Phase...
Repotrectinib by Bristol-Myers Squibb for Salivary Gland Cancer: Likelihood of Approval
Repotrectinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Salivary Gland Cancer. According to GlobalData,...
Repotrectinib by Bristol-Myers Squibb for Glioblastoma Multiforme (GBM): Likelihood of Approval
Repotrectinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData,...
Repotrectinib by Bristol-Myers Squibb for Liver Failure (Hepatic Insufficiency): Likelihood of Approval
Repotrectinib is under clinical development by Bristol-Myers Squibb and currently in Phase I for Liver Failure (Hepatic Insufficiency). According to...